PMID- 26339367
OWN - NLM
STAT- MEDLINE
DCOM- 20160614
LR  - 20231104
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 8
IP  - 7
DP  - 2015
TI  - HER2 status in molecular apocrine breast cancer: associations with clinical, 
      pathological, and molecular features.
PG  - 8008-17
AB  - Molecular apocrine breast cancer (MABC) is a distinct subtype of breast cancer. 
      The purpose of this study was to investigate the relationship between HER2 status 
      and clinicopathologic characteristics of MABCs from Chinese Han cohort. A cohort 
      of 90 MABC patients were enrolled. Immunohistochemical method was performed to 
      analyze the molecular expression, and the human epidermal growth factor receptor 
      2 (HER2) amplification was verified by fluorescence in situ hybridization (FISH). 
      By studying these 90 MABC cases, the majority of studied patients were 
      premenopausal young women (median age 48 yr) with high grade tumors. We also 
      found that MABCs had high positive expression rates of HER2, CK8, CD44, CD166, 
      p53 and BRCA1, the elevated Ki-67 labeling index, and favorable prognosis. There 
      was a significantly higher incidence of lymph node metastasis and lower CD166 
      positive rate in HER2-negative patients compared to HER2-positive patients (54.5% 
      vs. 37.0%, P = 0.044 and 72.7% vs. 91.3%, P = 0.021, respectively). The CK5/6 and 
      EGFR expression rates were significant higher in HER2-negative cases than in 
      HER2-positive cases, suggesting that there is overlap between MABC with 
      HER2-negative phenotype and basal-like breast cancer. In addition, HER2 positive 
      was found to be significantly associated a poor overall survival in MABCs. In 
      conclusion, HER2 are highly expressed, and HER2 positivity could be considered as 
      a significant biomarker of poor prognosis in MABC. The results also suggest that 
      a subtype tumor with distinct patterns of molecule expression depending on HER2 
      status presented in MABC.
FAU - Guo, Wenwen
AU  - Guo W
AD  - Department of Pathology, The Second Affiliated Hospital of Nanjing Medical 
      University Nanjing 210011, China ; Clinical Molecular Diagnostic Center, The 
      Second Affiliated Hospital of Nanjing Medical University Nanjing 210011, China.
FAU - Wang, Wei
AU  - Wang W
AD  - Department of Breast Surgery, Xuzhou Central Hospital Xuzhou 221009, China.
FAU - Zhu, Yun
AU  - Zhu Y
AD  - Department of Pathology, The First Affiliated Hospital with Nanjing Medical 
      University Nanjing 210029, China.
FAU - Zhu, Xiaojing
AU  - Zhu X
AD  - Department of Pathology, Jiangsu Province Academy of Traditional Chinese Medicine 
      Nanjing 210028, China.
FAU - Shi, Zhongyuan
AU  - Shi Z
AD  - Department of Pathology, Jiangsu Province Academy of Traditional Chinese Medicine 
      Nanjing 210028, China.
FAU - Wang, Yan
AU  - Wang Y
AD  - Department of Pathology, The Second Affiliated Hospital of Nanjing Medical 
      University Nanjing 210011, China.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20150701
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*analysis/genetics
MH  - Breast Neoplasms/*chemistry/classification/genetics/mortality/pathology/therapy
MH  - Cell Proliferation
MH  - China
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Kaplan-Meier Estimate
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Receptor, ErbB-2/*analysis/genetics
MH  - Tissue Array Analysis
MH  - Treatment Outcome
PMC - PMC4555695
OTO - NOTNLM
OT  - FISH
OT  - HER2
OT  - basal-like breast cancer
OT  - biomarker
OT  - molecular apocrine breast cancer
EDAT- 2015/09/05 06:00
MHDA- 2016/06/15 06:00
PMCR- 2015/07/01
CRDT- 2015/09/05 06:00
PHST- 2015/05/14 00:00 [received]
PHST- 2015/06/26 00:00 [accepted]
PHST- 2015/09/05 06:00 [entrez]
PHST- 2015/09/05 06:00 [pubmed]
PHST- 2016/06/15 06:00 [medline]
PHST- 2015/07/01 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2015 Jul 1;8(7):8008-17. eCollection 2015.